The UK pharma industry saw a spike in public trust and favourability amid the COVID-19 pandemic that, so far, shows little sign of wearing off, according to a new poll.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh